The Latest Cardiac and Vascular News
Advancing Remote Cardiac Monitoring with Faster Insights, Greater Comfort, and Seamless Connectivity MOUNT LAUREL, N.J., April 22, 2026 /PRNewswire/ — RhythMedix, LLC (RhythMedix), a nationwide U.S.-based cardiac monitoring company, today announced the launch of its next-generation…
Kestra Medical Technologies booth at HRS 2026
Kestra Medical Technologies will showcase its Cardiac Recovery System® platform at Heart Rhythm 2026 (HRS). At Booth 2119, attendees can explore the platform through an immersive multimedia experience, experience the ASSURE® system firsthand, and review clinical data from the ACE-PAS study.
KIRKLAND, Wash., April 22, 2026 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced it will exhibit at Heart Rhythm 2026, the annual meeting of the Heart Rhythm Society (HRS) taking place April 23–26 in Chicago. The company will showcase its Cardiac Recovery System® platform—a modern, integrated approach to managing sudden cardiac arrest (SCA) risk that unites proven therapy, actionable clinical insights, and ongoing patient support to enhance protection and optimize care. Kestra, one of the fastest-growing companies in medical technology, continues to build momentum as clinicians increasingly shift toward more connected approaches to SCA risk management. At HRS, attendees will see why more clinicians are turning to Kestra to improve patient protection and better manage risk during the most vulnerable stages of recovery. The ASSURE® WCD is at the center of the Cardiac Recovery System platform. Insights from the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS)—the largest prospective study of wearable defibrillators to date—demonstrate robust real-world performance and continue to guide innovation across the platform. At HRS, Kestra is launching a recently FDA-approved ASSURE WCD algorithm update that builds on market-leading clinical performance and applies real-world data to further enhance patient protection and advance care. “At Kestra, innovation is a core principle, so we are excited to further advance the clinical benefits of the ASSURE WCD with this new algorithm. We’re seeing a clear shift in how clinicians approach SCA risk, with a growing emphasis on patient compliance and connected models of care,” said Brian Webster, President and Chief Executive Officer. “HRS is a pivotal moment to engage with prescribers and demonstrate how our clinically informed innovation is driving that momentum—delivering meaningful improvements for clinicians and their patients.” Kestra will be located at Booth 2119, where attendees can experience the ASSURE system firsthand, explore the Cardiac Recovery System platform through an immersive multimedia experience, and review clinical data from ACE-PAS. About Kestra Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com. Forward-Looking StatementsExcept where otherwise noted, the information contained in this press release is as of April 22, 2026. Statements in this press release that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; and other risks and uncertainties, including those described under the heading “Risk Factors” in Kestra’s Annual Report on Form 10-K for the fiscal year ended April 30, 2025 filed with the U.S. Securities and Exchange Commission (“SEC”) on July 17, 2025, and in other periodic reports filed by Kestra with the SEC. These filings are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/93288f45-4a54-4de1-b66e-207047603f80 CONTACT: Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com
Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com
ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the US have been successfully treated using MAGiC™.
NEW YORK, April 21, 2026 /PRNewswire/ — UltraGreen Cardiac Technologies, a business unit of UltraGreen.ai (“UltraGreen” or the “Company”), a global leader in digital health solutions, today announced a strategic partnership with LifeSignals, a pioneer in wearable biosensor technology, to…
New publications in Heart Rhythm and Europace demonstrate how single-beat mapping provides instant clinical clarity, optimizing ablation strategies and improving patient safety. MADRID, April 21, 2026 /PRNewswire/ — Corify Care today announced a major clinical milestone with the…
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its nPulse™ Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois. At HRS 2026, Pulse Biosciences will present late‑breaking clinical trial updates, highlighting European feasibility study one‑year outcomes
MADRID, April 17, 2026 /PRNewswire/ — Corify Care today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the ACORYS® System, the first imageless, non-invasive cardiac mapping platform capable of delivering a global, four-chamber view of cardiac…
NEW YORK–(BUSINESS WIRE)– #BetterOutcomes–AccurKardia, an ECG analytics software company focused on establishing ECG as a broad biomarker, today announced a multi-year agreement with Specialized Medical. Under this partnership, AccurKardia’s FDA-cleared Class II software as a medical device (SaMD), AccurECG™ 2.0, is actively powering Specialized Medical’s state-of-the-art cardiac monitoring operations, which currently serve more than 20 clinics, medical practices, and hospitals across four states. Specialized
Now CE Marked, the Kardia 12L ECG System leverages AI to detect 35 cardiac determinations, simplifying the ECG process and expediting access to critical heart data
AliveCor’s Kardia 12L launches in Europe
AliveCor Launches AI-Powered Kardia 12L in Europe: The World’s First Handheld 12-Lead ECG with a Unique Single-Cable Design
MOUNTAIN VIEW, Calif., April 15, 2026 (GLOBE NEWSWIRE) — AliveCor, the global leader in AI-powered cardiology, today announced it has received CE Mark (Conformité Européenne) for the Kardia™ 12L electrocardiogram (ECG) System powered by KAI™ 12L AI technology. Kardia 12L is the world’s first AI-powered, portable 12-lead ECG system featuring a unique, single-cable design for Health Care Professionals (HCPs). Powered by KAI 12L, the system enables faster, easier detection of 35 cardiac determinations, including acute myocardial infarction (MI) and the most common types of cardiac ischemia. “Securing CE Mark for the Kardia 12L is a defining moment in our strategy to scale AliveCor’s global footprint,” said Simona Esposito, Senior Vice President of Sales, Global Markets at AliveCor. “Our priority is to get this life-saving technology into the hands of as many clinicians as possible, especially in settings where traditional, bulky ECG carts simply aren’t practical. By simplifying the hardware without sacrificing diagnostic depth, we are fundamentally improving access to high-quality cardiac care and reducing the burden of cardiovascular disease in the EU.” Technical Specifications and Capabilities of Kardia 12LKardia 12L is the portable, AI-guided, 12-lead ECG solution whose measurements and ECG interpretation are highly similar to standard 12-lead ECG solutions, right at the point of care, enabling rapid acquisition of complete ECG information and offering a better patient experience. 35 Cardiac Determinations: KAI 12L is the first AI of its kind to detect life-threatening cardiac conditions using a reduced leadset and can identify a comprehensive range of conditions. This includes 14 arrhythmias and 21 morphologies including serious conditions like acute MI and the most common types of cardiac ischemia.Rapid Detection: Specifically designed to expand access to accurate cardiac data across diverse healthcare and acute settings, the system allows for the rapid identification of life-threatening conditions like heart attack.Operational Efficiency: The device weighs just 0.13 kg (0.3 lbs) and is battery-operated, allowing it to be used by HCPs in primary care, urgent care, pharmacy, the home and rural clinics where traditional ECG machines may be impractical due to their size and complexity.Improved Patient and Clinician Experience: The simplified five-electrode setup makes it less invasive for patients, who do not need to fully disrobe during a reading, and typically allows for faster acquisition. Research has shown nearly a 30% reduction in ECG acquisition time compared to standard 12-lead setups. “In a fast-paced clinical environment, every second counts, but we cannot sacrifice accuracy for speed,” said Dr. Alejandro Barbagelata, Adjunct Assistant Professor of Medicine and Cardiology at Duke University. “Kardia 12L offers a unique combination of portability and diagnostic depth, allowing HCPs to make informed care decisions. By streamlining the acquisition process, it enables clinicians to identify life-threatening conditions like MI much faster, leading to better patient outcomes across the board.” Since its FDA clearance and subsequent launch in the United States in June 2024, Kardia 12L has seen growing global adoption including in India, Australia, New Zealand, Vietnam and Canada. The system has been adopted by clinicians across the globe capturing critical heart data on tens of thousands of patients. Most notably, the system has identified over 4,000 instances of MI and ischemia, facilitating life-saving care for those who need it most. This launch comes at a pivotal time, as the European Union reinforces its commitment to tackling cardiovascular diseases–the leading cause of mortality in Europe–through its EU Cardiovascular Health Plan, which prioritizes early detection, prevention, and improved access to care. Kardia 12L will be first available for healthcare providers in France, Germany, Italy, Spain, and the United Kingdom, and will be followed by additional European countries soon. For more information, please visit: https://alivecor.com/uk/products/kardia12l. Frequently Asked Questions Where is the Kardia 12L ECG System available in Europe? The Kardia 12L ECG System will be first available for healthcare providers in France, Germany, Italy, Spain, and the United Kingdom, followed by additional European countries soon. This follows the recent receipt of the CE Mark, allowing for its distribution across the European Economic Area. How does Kardia 12L compare to traditional ECG carts? Unlike traditional ECG carts that require 10 leads and bulky hardware, the Kardia 12L uses a unique single-cable, five-electrode design. It is pocket-sized, battery-operated, and uses AI to detect 35 cardiac determinations, making it significantly more portable and faster to deploy in a variety of healthcare facilities and acute settings, including primary and urgent care offices, mobile clinics, in pharmacies, by HCPs in home visits and other underserved or rural venues. How many and what cardiac conditions can the Kardia 12L detect? Powered by KAI 12L AI, the system is cleared to detect 35 cardiac determinations, including 14 arrhythmias (such as Atrial Fibrillation and Atrial Bigeminy) and 21 morphologies. Does the Kardia 12L require specialized training for clinicians? No. The device requires minimal self-guided training. Its simplified five-electrode placement is more intuitive than standard 10-lead setups, which can reduce the risk of lead reversal and shorten the time required for patient preparation. Is the Kardia 12L ECG System intended for home use? The Kardia 12L is intended for use by healthcare professionals in clinical environments including hospitals, urgent care centers, primary care practices, rural clinics, and pharmacy and home visits by an HCP. About AliveCorAliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) devices, is transforming cardiology with its medical-grade AI solutions. The company was named to the inaugural TIME World’s Top Health Tech Companies 2025 list – recognition of its commitment to delivering innovative devices and services that empower patients and physicians with personalized, actionable heart data. With over 350 million ECGs recorded, the company’s Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds. The company’s latest offering, Kardia 12L ECG System, powered by KAI 12L cleared to detect 39 cardiac conditions (with determination availability varying by geography), was designed exclusively for use by healthcare providers. AliveCor’s enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas. AliveCor is a privately held company headquartered in Mountain View, Calif. For more information, visit alivecor.com and follow us on LinkedIn, X, Instagram and Facebook. Media ContactMorgan Mathis Director of Corporate Communications, AliveCor press@alivecor.com Sales Contact OUSenquiries@alivecor.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d510c9dc-7eb1-45bd-ba22-aa01f14d3e40
Clinical Evidence Further Demonstrates Efficacy and Accuracy of VIVO for Ventricular ProceduresFORT MILL, S.C., April 13, 2026 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company”) today announced that the results of a recently concluded VIVO study have been accepted in EP Europace, the leading European electrophysiology journal. The EP Europace journal provides an avenue of communication for top-quality European and international original, scientific work and reviews in the fields of arrhythmias, pacing and cellular electrophysiology. The journal offers readers a collection of contemporary, original, peer-reviewed papers, invited papers and editorial comments, together with book reviews and correspondence. The accepted manuscript titled “Accuracy of a non-invasive electrocardiographic imaging system in scar-dependent ventricular tachycardia: Relationship to arrhythmogenic substrate and imaging defined scar” highlights the feasibility of VIVO for scar-related ventricular tachycardia (VT) was led by Professor Tarv Dhanjal, MBChB(hons) PhD FRCP FESC FEHRA, Professor of Cardiology (University of Warwick). This study included 31 patients and mapped 48 VTs with VIVO and standard of care electroanatomical mapping systems to determine accuracy. The study concluded that ECGi mapping with VIVO can accurately predict the arrhythmogenic substrate for scar-dependent VT and incorporation of ECGi mapping to conventional VT ablation workflows may improve procedural efficiency. Of additional importance, this study compares VIVO’s predictability of epicardial VTs to a four step ECG based algorithm. In patients with Non-ischemic cardiomyopathy (NICM), the VIVO localization had a 100% specificity and 66.7% sensitivity, while a traditional four-step ECG-based algorithm had a sensitivity and specificity of 50% and 0%, further demonstrating VIVO’s capabilities to improve procedural workflow.David Jenkins, CEO of Catheter Precision, says, “This study demonstrates that VIVO works in a wide range of patients, including those with scar related ventricular tachycardia and that it can improve procedural workflow and reduce procedure time even in very difficult procedures like epicardial VT. We are very pleased with the outcomes of this study and plan to start a larger, multi-center study later this year to prove out these results on a larger scale.” About VIVO™ Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark. About Catheter PrecisionCatheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “anticipate,” “potential,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, expectations regarding potential strategic transactions, valuation outcomes, market opportunities, and the Company’s growth strategy. These statements involve risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the Company’s filings with the SEC, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements. CONTACTS: Investor Relations973-691-2000IR@catheterprecision.com # # #
